3 buys whatever the EU referendum result: AstraZeneca plc, YouGov plc and Cobham plc

These three stocks look set to perform well whether Leave or Remain win today’s vote: AstraZeneca plc (LON: AZN), YouGov plc (LON: YOU) and Cobham plc (LON: COB).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

So, the EU referendum is finally upon us and many investors may be wondering which stocks are set to perform well given a Remain or Leave victory. Certainly, there are many examples of potential winners given either result, but there are also stocks that could be set to record stunning share price gains whether the UK stays in or quits the EU.

One such is AstraZeneca (LSE: AZN). Its status as an international pharmaceutical company means that it’s more dependent on the ups and downs of the patent cycle rather than the booms and busts of the UK economy. And on the patent front it appears to be making strong progress with its acquisition strategy improving AstraZeneca’s treatment pipeline so that it’s on track to return to positive earnings growth over the medium term.

Furthermore, AstraZeneca is unlikely to slow down its pace of acquisitions, with the company having excellent cash flow, which affords it tremendous financial firepower. For example, in the last three years AstraZeneca’s free cash flow has averaged $4.9bn per annum and so it seems able to afford to spend further in order to beef up its pipeline. And with that cash flow supporting a yield of 5%, the company’s income potential remains upbeat – especially while interest rates are at rock bottom.

Headline grabber

Also offering upbeat future prospects whatever the EU referendum result is YouGov (LSE: YOU). Clearly, it has been in the headlines a lot more than usual recently, with its polling segment offering up predictions of whether Leave or Remain will win the vote. This could provide a boost to YouGov’s earnings in the short run and with the company expected to increase its net profit by 11% this year and by a further 13% next year, it seems to be performing well.

In fact, YouGov has an excellent track record of earnings growth, with its bottom line rising in each of the last five financial years. And with its shares trading on a price-to-earnings growth (PEG) ratio of just 1.6, they seem to offer a wide margin of safety for long-term investors. Therefore, whether the UK leaves or stays in the EU, YouGov seems to be a sound buy.

Contract wins

Meanwhile, aerospace company Cobham (LSE: COB) has today announced that it has been awarded a contract by Airbus to provide satellite communications to single-aisle and long-range aircraft families. The contract could be worth as much as $200m and will see aircraft being fitted with the communications technology from 2018 onwards. It’s the second major contract Cobham has won with Airbus in the last two months.

Clearly, Cobham has experienced a challenging period of late and its bottom line is due to fall by 22% this year. However, with it being geographically highly diversified and more reliant on the global economy than the UK economy, its return to growth next year seems to be less dependent on the outcome of today’s referendum than is the case for a number of its index peers. And with it trading on a price-to-earnings (P/E) ratio of 11.9, it seems to offer a sufficiently wide margin of safety to merit investment at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »